PhaseBio and SFJ to Start China trial of Reverse Agent for Antiplatelet
publication date: Aug 10, 2021
PhaseBio Pharma and SFJ Pharma announced their partnered drug, bentracimab, was approved to start a China Phase III trial. PB2452 is a reversal agent for an antiplatelet therapy, ticagrelor, in major bleeding and urgent surgery situations. In January 2020, the Bay Area's SFJ entered a $120 million deal to support clinical trials of the drug, which was developed by Pennsylvania's PhaseBio. SFJ assumed a role in the clinical trials of the drug outside of the US and will be paid up to five times the $120 million in milestones over eight years. More details....
Stock Symbols: (NSDQ: PHAS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.